TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04061720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Chronic Care
Description: Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
Study: NCT02617277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 (adavosertib) is available in capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 (adavosertib) is available in capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 (adavosertib) is available in capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 (adavosertib) is available in capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 (durvalumab) will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 (durvalumab) will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 (durvalumab) will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 (durvalumab) will be administered by IV infusion.
Study: NCT03614962

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warmth + TENS
Description: A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warmth + TENS
Description: A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warmth + placebo-TENS
Description: A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warmth only
Description: A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: control
Description: No warmth pad and TENS electrodes presented in the cap.
Study: NCT00679289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDI
Description: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
Study: NCT02130453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.

Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: 0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
Study: NCT00762840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Apexum Protocol
Description: using the apexum kit for minimally invasive removal of periapical lesion tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional endodontic procedure
Description: Standard root canal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endodontic procedure
Description: Standard root canal treatment
Study: NCT03999268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-START
Description: Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Insulin Administration Education
Description: Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insulin Administration Education
Description: Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
Study: NCT02481843

Intervention type: OTHER
Intervention: 2 hours of hyperoxia (FiO2 = 1)
Description: Patients received 2 hours of hyperoxia at FiO2 = 1
Study: NCT03216902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution
Description: Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ultra-low dose of DE-126 Ophthalmic Solution
Description: Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical low dose of DE-126 Ophthalmic Solution
Description: Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical medium dose of DE-126 Ophthalmic Solution
Description: Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical high dose of DE-126 Ophthalmic Solution
Description: Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% Latanoprost Ophthalmic Solution
Description: 0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
Study: NCT02088632

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinumtoxina
Description: Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Normal saline is sterile sodium chloride without and preservatives.
Study: NCT02213328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
Study: NCT01280734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin (R) 2 mg
Description: One 2 mg tablet at 23:00

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stilnox (R) 10 mg
Description: One 10 mg encapsulated tablet at 23:00

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet or encapsulated tablet at 23:00
Study: NCT03402880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03691948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Responsible Opioid Prescriber Education (ROPES)
Description: The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Control
Description: An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
Study: NCT00280826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
Study: NCT03581123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported-Self Management (SSM)
Description: Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Description: SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SMT + SSM
Description: Combination Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Description: Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
Study: NCT04483934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dermal fibroblasts
Description: Cultured autologous dermal fibroblasts.~For PR: The name dermal fibroblasts is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED phototherapy
Description: LED phototherapy
Study: NCT01659398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counterpulsation (EECP)
Description: A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
Study: NCT01790360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigation (PN) Intervention
Description: Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives (FI) Intervention
Description: After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
Study: NCT00595972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECF-endostar
Description: Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study: NCT00730314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: hematopoietic stem cell transplantation conditioning regimen depending on graft source

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: hematopoietic stem cell transplantation conditioning regimen depending on graft source
Study: NCT02302066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Description: TDV subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV Placebo
Description: Placebo-matching vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV Placebo
Description: Placebo-matching vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV Placebo
Description: Placebo-matching vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TDV Placebo
Description: Placebo-matching vaccine
Study: NCT04566588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EAR HoLEP
Description: early apical release holmium enucleation of the prostate (EAR HoLEP), as a surgical treatment for benign prostatic hyperplasia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic HoLEP
Description: classic holmium enucleation of the prostate as a surgical treatment for benign prostatic hyperplasia
Study: NCT01203839

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: multiple beams utilizing either intensity-modulated or 3D-conformal techniques
Description: A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
Study: NCT03492892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Stimulate acupoint with filiform needles to restore the healthy condition of patients

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Stimulate non-acupoint with filiform needles to treat the condition of patients
Study: NCT01975220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin XR, FDC
Description: Experimental: high dose empagliflozin/metformin XR, FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin XR FDC
Description: Experimental: low dose empagliflozin/metformin XR, FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Empagliflozin/1000 mg Metformin XR, FDC
Description: Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
Study: NCT00679289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDI
Description: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDI
Description: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW2871
Description: 5 mg/m\^2 IV every 2 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW2871
Description: 10 mg/m\^2 IV every 2 weeks until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW2871
Description: 20 mg/m\^2 IV every 2 weeks until disease progression
Study: NCT00264069

Intervention type: DRUG
Intervention: antipsychotic
Description: as prescribed
Study: NCT01975220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/2 tablets Metformin XR
Description: Active Comparator: 1x empagliflozin/2x metformin XR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/3 tablets Metformin XR
Description: Active Comparator: 1x empagliflozin/3x metformin XR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Empagliflozin/2 tablets Metformin XR
Description: Active Comparator: 1x empagliflozin/2x metformin XR tablets
Study: NCT03581877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKOS
Description: As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
Study: NCT00538174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily up, to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily up, to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily up, to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets, Oral, 0 mg, once daily, up to 14 days
Study: NCT04707339

Intervention type: PROCEDURE
Intervention: Appendicectomy
Description: Laparoscopic or Open Appendicectomy

Intervention type: PROCEDURE
Intervention: Appendicectomy
Description: Laparoscopic or Open Appendicectomy
Study: NCT02180438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
Study: NCT02460263

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tablo Hemodialysis System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablo Hemodialysis System
Study: NCT03163576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate Binder
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Binder
Description: tablets
Study: NCT02312401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-parametric MRI(MP-MRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced MRI (DCE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy